TITLE

Impact of Cytomegalovirus Match on Survival After Cardiac and Lung Transplantation

AUTHOR(S)
Bonatti, Hugo; Tabarelli, Walther; Ruttmann, Elfriede; Kafka, Reinhold; Larcher, Clara; Höfer, Daniel; Klaus, Alexander; Laufer, Günther; Geltner, Christian; Margreiter, Raimund; Müller, Ludwig; Antretter, Herwig
PUB. DATE
August 2004
SOURCE
American Surgeon;Aug2004, Vol. 70 Issue 8, p710
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Acute cytomegalovirus (CMV) disease and indirect effects caused by the virus alter the outcome after solid organ transplantation. Long-term results after 54 lung and 139 cardiac transplants at a single center have been retrospectively analyzed with regard to CMV status. Standard CMV prophylaxis consisted of ganciclovir for 100 days. Lung recipients were pretransplant CMV negative in 32 per cent as compared to heart recipients with 23 per cent. Patient survival after mismatch transplants (donor positive, recipient negative) was significantly reduced as compared to the other match groups (42% vs 76% at five years, P = 0.01). In heart recipients, CMV positive patients receiving a CMV negative graft showed best survival, whereas in the group of lung recipients negative/negative matched transplants produced best results. In both groups, CMV negative grafts had a better outcome than CMV positive grafts, and a survival difference between heart and lung recipients was only observed in recipients of a CMV positive grafts. Despite ganciclovir prophylaxis, CMV match remains an important factor for survival follwing heart and, even more profoundly, lung transplantation. Because survival was least favorable in the mismatched group, prophylactic regimens warrant improvement. For CMV negative lung recipients, CMV matching might be considered.
ACCESSION #
14146684

 

Related Articles

  • transplantation.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2361 

    An encyclopedia entry for "transplantation" is presented. It refers to the grafting of living tissue from its normal position to another site or the transplantation of organs, such as heart and lungs, or tissue from one person to another. In dentistry, the term is used to the transfer of a tooth...

  • Allograft Rejection Predicts the Occurrence of Late-Onset Cytomegalovirus (CMV) Disease among CMV-Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral Ganciclovir. Razonable, Raymund R.; Rivero, Antonio; Rodriguez, Aurelio; Wilson, Jennie; Daniels, Judith; Jenkins, Gregory; Larson, Timothy; Hellinger, Walter C.; Spivey, James R.; Paya, Carlos V. // Journal of Infectious Diseases;12/1/2001, Vol. 184 Issue 11, p1461 

    The natural history of cytomegalovirus (CMV) disease associated with solid organ transplan-tation has been modified as a result of the widespread use of antiviral prophylaxis. Anecdotal reports have indicated a reduction of CMV disease at the expense of its later occurrence after completion...

  • Costs and consequences of cytomegalovirus disease. Schnitzler, Mark A. // American Journal of Health-System Pharmacy;12/1/2003, Vol. 60 Issue 23, pS5 

    Describes the impact of prophylactic oral ganciclovir therapy on the incidence of cytomegalovirus (CMV) disease. Identification of CMV disease as a cause of morbidity and mortality in solid organ transplant recipients; Observation that CMV disease increases the risk of graft failure which...

  • New prophylactic treatment strategy for cytomegalovirus disease. Lake, Kathleen D. // American Journal of Health-System Pharmacy;12/1/2003, Vol. 60 Issue 23, pS13 

    Describes the pharmacology, pharmacokinetics, safety and efficacy of valganciclovir, an oral prodrug for ganciclovir, used to prevent cytomegalovirus (CMV) disease in solid organ transplant recipients. Development of valganciclovir to overcome the disadvantages associated with ganciclovir; Oral...

  • Formulary considerations for drugs used to prevent cytomegalovirus disease. Pescovitz, Mark D. // American Journal of Health-System Pharmacy;12/1/2003, Vol. 60 Issue 23, pS17 

    Describes four types of therapeutic strategies for managing cytomegalovirus (CMV) infections in solid organ transplant recipients, the mechanism of action and efficacy of drugs use for prophylaxis and the criteria for evaluating drugs for inclusion in a formulary. Criteria for deciding which...

  • Valganciclovir: A Review of its Use in the Management of CMV Infection and Disease in Immunocompromised Patients. Cvetković, Risto S.; Wellington, Keri // Drugs;2005, Vol. 65 Issue 6, p859 

    Valganciclovir (Valcyteâ„¢) is an orally administered prodrug of the standard anti-cytomegalovirus (CMV) drug ganciclovir. Valganciclovir is as effective as intravenous ganciclovir for the treatment of AIDS-related CMV retinitis, and oral ganciclovir for the prophylaxis of CMV infection and...

  • Valganciclovir economical for CMV prophylaxis.  // PharmacoEconomics & Outcomes News;9/22/2007, Issue 537, p6 

    The article discusses research being done on the use of oral valganciclovir for the treatment of cytomegalovirus (CMV) infection among solid organ transplant recipients. It references a study by F. Oppenheimer and colleagues, published in the July-August 2007 issue of "Clinical Transplantation."...

  • Use of Valganciclovir for Prevention and Treatment of Cytomegalovius Disease. Snydman, David R. // Clinical Infectious Diseases;1/1/2008, Vol. 46 Issue 1, p28 

    The article comments on the paper "Valganciclovir As Preemptive Therapy or Treatment for Cytomegalovirus Disease in Solid Organ Transplantation," by O. Len and colleagues, published within this issue. In this paper, Len and colleagues discussed the efficacy of valganciclovir in preventing and...

  • Lung and heart-lung transplantation. Date, Hiroshi; Sweet, Stuart C. // Cardiology in the Young;May2009, Vol. 19 Issue S1, p45 

    The article offers information concerning lung and heart-lung transplantation which remain as the therapeutic options when there is a failure on medical therapy. It notes that it commonly performed to patient with congenital cardiac anomalies. It suggests that long-term infusion of epoprostenol...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics